skip to Main Content
Tilray, Inc. Announces Closing of US$450 Million 5.00% Convertible Notes Offering

PRESS RELEASE

NANAIMO, British Columbia – Tilray, Inc. (NASDAQ:TLRY), a global leader in cannabis research, cultivation, production and distribution, today announced that it has closed its offering of 5.00% Convertible Senior Notes due 2023 (the “notes”) for gross proceeds of US$450 million in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Any notes sold in Canada were sold to accredited investors pursuant to an exemption from the prospectus requirements of Canadian securities laws.

Tilray estimates that the net proceeds from the offering is approximately US$435 million, after deducting the initial purchasers’ discount and estimated offering expenses payable by Tilray.  Tilray intends to use the net proceeds from this offering for working capital, future acquisitions and general corporate purposes, and to repay the approximately US$9.1 million existing mortgage related to its facility in Nanaimo, British Columbia.

Cowen, BofA Merrill Lynch and BMO Capital Markets acted as joint book-running managers for the offering.  Roth Capital Partners, Eight Capital and Northland Capital Markets acted as co-managers for the offering.

The notes are senior unsecured obligations of Tilray and bear an interest at a rate of 5.00% per year, payable semiannually in arrears on April 1 and October 1 of each year, beginning on April 1, 2019.  The notes mature on October 1, 2023, unless earlier repurchased, redeemed or converted.

The initial conversion rate for the notes is 5.9735 shares of Class 2 common stock per US$1,000 principal amount of notes (which is equivalent to an initial conversion price of approximately US$167.41 per share). Conversions of the notes will be settled in cash, shares of Tilray’s Class 2 common stock or a combination thereof, at Tilray’s election. The initial conversion price represents a conversion premium of approximately 15% over the last reported sale price of US$145.57 per share of Tilray’s Class 2 common stock on the Nasdaq Global Select Market on October 4, 2018.

Neither the notes, nor any shares of Tilray’s Class 2 common stock issuable upon conversion of the notes, have been registered under the Securities Act or any state securities laws, or qualified for distribution by prospectus in Canada, and unless so registered, may not be offered or sold in the United States absent registration or an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and other applicable securities laws, or sold in Canada absent an exemption from the prospectus requirements of Canadian securities laws.

This press release is neither an offer to sell nor a solicitation of an offer to buy any securities, nor shall it constitute an offer, solicitation or sale of any securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

For more information, please visit www.tilray.com.

This Post Has 0 Comments

Leave a Reply

Your email address will not be published. Required fields are marked *

Recent Stories

Guns or marijuana, but not both

While marijuana became legal for adults to purchase in Montana on New Year’s Day, a key federal agency has confirmed a fact underreported in coverage of the state’s new marijuana program: It remains illegal under federal law for individuals to simultaneously possess marijuana or marijuana products and firearms, and penalties for violating that law are…

As Oklahoma’s medical marijuana industry booms, regulators struggle to keep up

Row by row, Oklahoma Bureau of Narcotics and Dangerous Drugs agents and Garvin County deputies cut down 2,500 marijuana plants and loaded them in a dump truck for destruction during an April 2021 raid near Pauls Valley. The grow operation had a Oklahoma Medical Marijuana Authority license, but had not obtained an additional permit from…

European Cannabis Round-Up; GW Pharma’s Cannabis Pipeline, Irish CBD In Court, UK Medical Cannabis Price Row, Italian Referendum, Poland And Malta

GW Pharmaceuticals has released further details of its cannabis development pipeline. With Epidiolex approved in the US last year it is also expecting approval for Sativex where two phase 3 trials are ongoing. Work is also underway on the use of Sativex in spinal cord injury, post-traumatic stress disorder and other forms of spasticity. Further…

ICYMI: Adding Marijuana to a NIST Handbook

by Hilary Bricken, Principle at Harris Bricken Not many people get excited about revisions and updates to the very dry National Institute of Standards and Technology  (“NIST”) handbooks. For example, the NIST 44 Handbook contains the “Specifications, Tolerances, and Other Technical Requirements for Weighing and Measuring Devices.” The handbooks are adopted every year at the…

More Categories

Back To Top
×Close search
Search